Literature DB >> 21538078

A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families.

Kathleen Y Yang1, Aaron B Caughey, Sarah E Little, Michael K Cheung, Lee-May Chen.   

Abstract

Women at risk for Lynch Syndrome/HNPCC have an increased lifetime risk of endometrial and ovarian cancer. This study investigates the cost-effectiveness of prophylactic surgery versus surveillance in women with Lynch Syndrome. A decision analytic model was designed incorporating key clinical decisions and existing probabilities, costs, and outcomes from the literature. Clinical forum where risk-reducing surgery and surveillance were considered. A theoretical population of women with Lynch Syndrome at age 30 was used for the analysis. A decision analytic model was designed comparing the health outcomes of prophylactic hysterectomy with bilateral salpingo-oophorectomy at age 30 versus annual gynecologic screening versus annual gynecologic exam. The literature was searched for probabilities of different health outcomes, results of screening modalities, and costs of cancer diagnosis and treatment. Cost-effectiveness expressed in dollars per discounted life-years. Risk-reducing surgery is the least expensive option, costing $23,422 per patient for 25.71 quality-adjusted life-years (QALYs). Annual screening costs $68,392 for 25.17 QALYs; and annual examination without screening costs $100,484 for 24.60 QALYs. Further, because risk-reducing surgery leads to both the lowest costs and the highest number of QALYs, it is a dominant strategy. Risk-reducing surgery is the most cost-effective option from a societal healthcare cost perspective.

Entities:  

Mesh:

Year:  2011        PMID: 21538078     DOI: 10.1007/s10689-011-9444-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  25 in total

1.  Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination.

Authors:  Allison A Cowett; Robert M Golub; William A Grobman
Journal:  Am J Obstet Gynecol       Date:  2006-03       Impact factor: 8.661

2.  Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.

Authors:  W McGuire; A I Neugut; S Arikian; J Doyle; C M Dezii
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 3.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium.

Authors:  W Burke; G Petersen; P Lynch; J Botkin; M Daly; J Garber; M J Kahn; A McTiernan; K Offit; E Thomson; C Varricchio
Journal:  JAMA       Date:  1997-03-19       Impact factor: 56.272

4.  Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.

Authors:  Kathleen M Schmeler; Henry T Lynch; Lee-may Chen; Mark F Munsell; Pamela T Soliman; Mary Beth Clark; Molly S Daniels; Kristin G White; Stephanie G Boyd-Rogers; Peggy G Conrad; Kathleen Y Yang; Mary M Rubin; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Karen H Lu
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

5.  Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.

Authors:  Victor R Grann; Judith S Jacobson; Dustin Thomason; Dawn Hershman; Daniel F Heitjan; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

7.  Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Authors:  Kristin Anderson; Judith S Jacobson; Daniel F Heitjan; Joshua Graff Zivin; Dawn Hershman; Alfred I Neugut; Victor R Grann
Journal:  Ann Intern Med       Date:  2006-03-21       Impact factor: 25.391

8.  Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome.

Authors:  Janice S Kwon; Charlotte C Sun; Susan K Peterson; Kristin G White; Molly S Daniels; Stephanie G Boyd-Rogers; Karen H Lu
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

9.  Cost-effectiveness of hormone replacement therapy in the menopause.

Authors:  M C Weinstein; I Schiff
Journal:  Obstet Gynecol Surv       Date:  1983-08       Impact factor: 2.347

10.  Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families.

Authors:  Lee-may Chen; Kathleen Y Yang; Sarah E Little; Michael K Cheung; Aaron B Caughey
Journal:  Obstet Gynecol       Date:  2007-07       Impact factor: 7.661

View more
  20 in total

Review 1.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

2.  American Society of Clinical Oncology policy statement on medicaid reform.

Authors:  Blase N Polite; Jennifer J Griggs; Beverly Moy; Christopher Lathan; Nefertiti C duPont; Gina Villani; Sandra L Wong; Michael T Halpern
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

3.  Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing.

Authors:  Jennifer M Matro; Karen J Ruth; Yu-Ning Wong; Katen C McCully; Christina M Rybak; Neal J Meropol; Michael J Hall
Journal:  J Genet Couns       Date:  2014-05-06       Impact factor: 2.537

4.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.

Authors:  Naohiro Tomita; Hideyuki Ishida; Kohji Tanakaya; Tatsuro Yamaguchi; Kensuke Kumamoto; Toshiaki Tanaka; Takao Hinoi; Yasuyuki Miyakura; Hirotoshi Hasegawa; Tetsuji Takayama; Hideki Ishikawa; Takeshi Nakajima; Akiko Chino; Hideki Shimodaira; Akira Hirasawa; Yoshiko Nakayama; Shigeki Sekine; Kazuo Tamura; Kiwamu Akagi; Yuko Kawasaki; Hirotoshi Kobayashi; Masami Arai; Michio Itabashi; Yojiro Hashiguchi; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2021-06-29       Impact factor: 3.402

Review 5.  Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention.

Authors:  Karen H Lu; Molly Daniels
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

6.  Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease.

Authors:  Jason D Wright; Rosa R Cui; Anqi Wang; Ling Chen; Ana I Tergas; William M Burke; Cande V Ananth; June Y Hou; Alfred I Neugut; Sarah M Temkin; Y Claire Wang; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2015-10-08       Impact factor: 13.506

7.  Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome.

Authors:  Matthew B Yurgelun; Rowena Mercado; Margery Rosenblatt; Monica Dandapani; Wendy Kohlmann; Peggy Conrad; Amie Blanco; Kristen M Shannon; Daniel C Chung; Jonathan Terdiman; Stephen B Gruber; Judy E Garber; Sapna Syngal; Elena M Stoffel
Journal:  Gynecol Oncol       Date:  2012-08-29       Impact factor: 5.482

8.  Genetic testing for lynch syndrome, an inherited cancer of the bowel, endometrium, and ovary.

Authors:  J Craig Strafford
Journal:  Rev Obstet Gynecol       Date:  2012

9.  A case of endometrial cancer in the context of a BRCA2 mutation and double heterozygosity for Lynch syndrome.

Authors:  Ping Gong; Sarah Charles; Norman Rosenblum; Zoe Wang; Agnieszka K Witkiewicz
Journal:  Gynecol Oncol Case Rep       Date:  2012-03-15

10.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts.

Authors:  Hans F A Vasen; Ignacio Blanco; Katja Aktan-Collan; Jessica P Gopie; Angel Alonso; Stefan Aretz; Inge Bernstein; Lucio Bertario; John Burn; Gabriel Capella; Chrystelle Colas; Christoph Engel; Ian M Frayling; Maurizio Genuardi; Karl Heinimann; Frederik J Hes; Shirley V Hodgson; John A Karagiannis; Fiona Lalloo; Annika Lindblom; Jukka-Pekka Mecklin; Pal Møller; Torben Myrhoj; Fokko M Nagengast; Yann Parc; Maurizio Ponz de Leon; Laura Renkonen-Sinisalo; Julian R Sampson; Astrid Stormorken; Rolf H Sijmons; Sabine Tejpar; Huw J W Thomas; Nils Rahner; Juul T Wijnen; Heikki Juhani Järvinen; Gabriela Möslein
Journal:  Gut       Date:  2013-02-13       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.